Article
JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6…
medRxiv · 2025 · Alexandrou, S.; Lee, C. S.; Fernandez, K. J.; Wiharja, C. E.; Eshraghi, L.; Reeves, J.; Reed, D. A.; Phan, Z.; Portman, N.; Milioli, H. H.; Nikolic, I.; Cadell, A. L.; Croucher, D. R.; Simpson, K. J.; Lim, E.; Hickey, T. E.; Millar, E. K. A.; Alves, C. L.; Ditzel, H. J.; Caldon, C. E.
Key facts
| Title | JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer |
|---|---|
| First author | Alexandrou, S.; Lee, C. S.; Fernandez, K. J.; Wiharja, C. E.; Eshraghi, L.; Reeves, J.; Reed, D. A.; Phan, Z.; Portman, N.; Milioli, H. H.; Nikolic, I.; Cadell, A. L.; Croucher, D. R.; Simpson, K. J.; Lim, E.; Hickey, T. E.; Millar, E. K. A.; Alves, C. L.; Ditzel, H. J.; Caldon, C. E. |
| Journal | medRxiv |
| Published | Jan 1, 2025 |
| DOI | 10.1101/2025.01.08.631992 |
| Devices mentioned | K041074, K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186 and 2 more |
| Product codes mentioned | CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, GKZ, KLB and 6 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1